Eyal Peer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eyal Peer has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Adi Zundelevich
Curesponse, Ltd., Rehovot 7670101, Israel
36 shared publications - Amy Zhang
Ontario Institute for Cancer Research, Toronto, ON, Canada
36 shared publications - Chani Stossel
Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel
36 shared publications - Dikla Atias
Pancreatic Cancer Translational Research Laboratory, Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
36 shared publications - Elina Haimov Talmoud
Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel
36 shared publications - Faiyaz Notta
Ontario Institute for Cancer Research, Toronto, Canada
36 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary table 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Clinical data of analyzed BRCA PDAC patients
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Clinical data of analyzed BRCA PDAC patients
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figure 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Mechanisms of resistance in glBRCA PDAC
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Mechanisms of resistance in glBRCA PDAC
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
In vivo growth kinetics and EVOC efficacy in acquired resistance model
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
In vivo growth kinetics and EVOC efficacy in acquired resistance model
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary table 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
In vivo, EVOC and clinical response
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
In vivo, EVOC and clinical response
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary figure 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Mechanisms of resistance in glBRCA PDAC
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Mechanisms of resistance in glBRCA PDAC
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
In vivo growth kinetics and EVOC efficacy in acquired resistance model
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
In vivo growth kinetics and EVOC efficacy in acquired resistance model
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
In vivo growth kinetics and EVOC efficacy in acquired resistance model
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
In vivo growth kinetics and EVOC efficacy in acquired resistance model